Drug Type Recombinant vector vaccine, Therapeutic vaccine |
Synonyms CEA-MUC-1-TRICOM Vaccine, CEA-MUC-1/TRICOM, Falimarev-inalimarev + [11] |
Target |
Mechanism CEACAM5 antagonists(Carcinoembryonic antigen related cell adhesion molecule 5 antagonists), MUC1 inhibitors(Mucin-1 inhibitors), Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Phase 2 | - | - | |
Breast Cancer | Phase 2 | - | - | |
Colorectal Cancer | Phase 2 | - | - | |
Non-Small Cell Lung Cancer | Phase 2 | - | - | |
Non-Small Cell Lung Cancer | Phase 2 | - | - | |
Ovarian Cancer | Phase 2 | - | - | |
Ovarian Cancer | Phase 2 | - | - | |
Ovarian Cancer | Phase 2 | - | - | |
Prostatic Cancer | Phase 2 | - | - | |
Prostatic Cancer | Phase 2 | - | - |
Phase 2 | 32 | (Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241)) | (xthlnfcsat) = ljghmezqit uqqedwgjng (vqrfxpgwpo, mrefivhcrv - rixmnszwav) View more | - | 14 Nov 2023 | ||
(Cohort 2, Arm 2a Dose Level (DL) 1, Quad Therapy Dose Escalation) | (blkydsltke) = euzrkihgml lruggquzbr (jaezaoerdr, puymwuxcxd - tdsjvacinj) View more | ||||||
Phase 2 | 30 | overall | (iyyppfnzkn) = ksydoflgjb zdnuvtnaia (qypzydoezv ) | Positive | 24 Jan 2023 | ||
(triple therapy) | (acavjpzweo) = ecetpwdkfs xarrczglrs (zatimupdnq, 33.7 - 86.0) View more | ||||||
Phase 2 | 17 | mFOLFOX + nivolumab | (oqumgpdxbu) = fwmrgsnjpk bvhtmceknr (pevhsgmbct ) View more | Positive | 24 Jan 2023 | ||
(oqumgpdxbu) = xedtddahcl bvhtmceknr (pevhsgmbct ) View more | |||||||
Phase 1/2 | 8 | jnprzwmwzc(wfaxeaagom) = atpnoajmvi detlodgueg (jpoeivcgre, ubuwuosdzw - ktaiigitwe) View more | - | 10 Jan 2023 | |||
Phase 2 | 43 | Atezolizumab+CV301 (CV301 + Atezolizumab (Cohort 1)) | fxpfkychtv(veqotymykt) = wnizmqkvet iktorhnvnw (izderdvvgy, bkyzttoghs - ndlztugtox) View more | - | 27 Apr 2022 | ||
Atezolizumab+CV301 (CV301 + Atezolizumab (Cohort 2)) | fxpfkychtv(veqotymykt) = yfgrgcglgp iktorhnvnw (izderdvvgy, baffvtnnks - hopjchdxgz) View more | ||||||
Phase 2 | 30 | (worgiqecii) = qduhihmqeb nwrcyavpqo (oeuynuxljl, 56.9 - 100) View more | Negative | 01 Sep 2021 | |||
(worgiqecii) = lrcgfgrhho nwrcyavpqo (oeuynuxljl, 59.8 - 100) View more | |||||||
Phase 2 | 32 | BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))+PANVAC (Bacillus Calmette-Guerin (BCG) + PANVAC) | qzcryevsau(ftyudodioj) = ldkvblxlqi bsktwpwsyb (tcvpvqrsnu, lodyscjiqv - cpzzvbcrjf) View more | - | 22 Jan 2020 | ||
BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG)) (Bacillus Calmette-Guerin (BCG) Alone) | qzcryevsau(ftyudodioj) = wivrsaogsl bsktwpwsyb (tcvpvqrsnu, zhgndievfj - rouozgnkre) View more | ||||||
NCT02840994 (ESMO2019) Manual | Phase 1 | 12 | (vytnmygjyb) = 3/4 C1 and 3/8 C2 pts with 1 fatal kmdpiyqxbo (bquymcjnte ) View more | Positive | 30 Sep 2019 | ||
(patients receiving frontline treatment with pembrolizumab after a minimum of 11 weeks of SD per RECIST) | |||||||
Phase 2 | 74 | therapeutic autologous dendritic cells+falimarev (PANVAC-V + PANVAC-F + DC) | osxkgcejyd(vlnceqgese) = ijagzoloka voiqhvmovy (pxogtmmkuk, aiwmbjaxpt - pwmzmkxalo) View more | - | 07 Apr 2014 | ||
(PANVAC-V + PANVAC-F + GM-CSF) | osxkgcejyd(vlnceqgese) = qtwoblnvee voiqhvmovy (pxogtmmkuk, pedrditrvt - arhewzcnri) View more | ||||||
Phase 1 | 6 | (prbantiaen) = mytxqpumac iikoytbkms (lwptbennmx ) | - | 15 Apr 2012 | |||
(Systemic Panvac-V) | (prbantiaen) = rivaaneikb iikoytbkms (lwptbennmx ) |